Boston, MA 06/19/2014 (wallstreetpr) – Aldeyra Therapeutics Inc (NASDAQ:ALDX) has named a new Chief Financial Officer, who will assume his position on June 23. The company noted that the new executive will help the company in its financial dealings through the clinical trials because he has widespread experience in the area.
The company announced that Stephen Tulipano, who boasts more than 27 years in handling accounting and financial issues with no less than 12 years service in the pharmaceutical industry, will be its CFO. He will report directly to the company’s President and Chief Executive Officer Todd C. Brady.
Pharmaceutical experience
Commenting on the appointment, CEO Brady observed that Tulipano will be an important asset to the company through the clinical development of its lead investigational drug known as NS2, which is targeted at the treatment of acute anterior uveitis and the Sjogren-Larsson Syndrome. The CEO also noted the significant experience that the incoming executive has in dealing with matters finance, especially in the pharmaceutical environment.
Can he deliver?
To the investor community, the question at this juncture is whether the new CFO officer will be equal to the task at Aldeyra Therapeutics Inc (NASDAQ:ALDX). Nobody can be sure about how things will progress in the company especially in the financial front under the leadership of Tulipano. However, it is worth noting that Tulipano has a proven track record serving in various finance positions in companies and accounting firms.
Most recently, Tulipano served Three Tulips Inc, which is an accounting and management advisory firm. He provided financial management and accounting services advisory. He was also the CFO at Javelin Pharmaceutical until the company was successfully sold to Hospira in 2010. As if that is not enough, he was the Director of Corporate Accounting at Biogen Inc, which is one of the oldest drug companies in the U.S. Of course, Tulipano also held various positions in several other companies and accounting entities.
Ready to work
The new Aldeyra Therapeutics Inc (NASDAQ:ALDX) finance chief revealed his excitement to join the company and went ahead to make the most important comment. He said that he would use his previous experiences in financial accounting, especially within the pharmaceutical industry, to contribute to the growth and long-term success of the company.
